一种包含所有主要不确定性的HDR前列腺近距离治疗鲁棒优化遗传算法。

IF 3.3 3区 医学 Q2 ENGINEERING, BIOMEDICAL
Andrew C Kennedy, Michael J J Douglass, Raghavendra V Gowda, Alexandre M C Santos
{"title":"一种包含所有主要不确定性的HDR前列腺近距离治疗鲁棒优化遗传算法。","authors":"Andrew C Kennedy, Michael J J Douglass, Raghavendra V Gowda, Alexandre M C Santos","doi":"10.1088/1361-6560/addf0b","DOIUrl":null,"url":null,"abstract":"<p><p><i>Objective.</i>In high-dose-rate prostate brachytherapy, uncertainties are likely to cause a deviation from the nominal treatment plan, potentially leading to failure in achieving clinical objectives. Robust optimisation has the potential to maximise the probability that objectives are met during treatment despite these uncertainties.<i>Approach.</i>A probabilistic robust optimiser that incorporating fourteen major uncertainty sources was developed and evaluated on 49 patients. Three objective functions were maximised to generate the approximate Pareto front of 200 robust-optimised plans, approximating the robustness of: (1) The minimum dose to the hottest 90% of the prostate (D90P), (2) The maximum dose to the urethra (D0.01 ccU), and (3) The maximum dose to the rectum (D0.1 ccR). Plans were then robustly evaluated using 1000 uncertainty scenarios each simulating a possible deviation from the planned treatment. The percentage of scenarios meeting theD90P,D0.01 ccU, andD0.1 ccRmetrics were determined, along with the overall pass rate, defined as the percentage of scenarios meting all three metrics simultaneously. These pass-rates, along with nominal metrics, were, were used to select the best robust-optimised plan. A radiation oncologist evaluated the best robust-optimised plans against the treatment planning system (TPS)-optimised plan for ten patients. The same selection criteria were then applied to a further cohort of 39 patients and the same plan comparisons performed.<i>Main results</i>. All best robust-optimised plans had higher overall pass-rates (mean: 50.7 ± 1.5%, SD: 14.2%) then TPS-optimised plans (mean: 32.0 ± 1.5%, SD: 12.3%). The meanD0.01 ccUpass-rate was 66.0 ± 1.3% (SD: 12.1) for the robust-optimised plans compared with 47.2 ± 1.3% (SD: 9.3%) for TPS-optimised plans. TheD90Ppass-rates was higher for robust-optimised plans (mean: 85.6 ± 1.1%, SD: 9.5%) then TPS-optimised (mean: 82.2 ± 1.1%, SD: 13.8%) in 36 patients.D0.1 ccRpass-rates remained consistently high for both optimisation methods.<i>Significance</i>. The robust optimisation algorithm generated plans with greater robustness than the TPS-optimised plans for nine out of ten patients evaluated by a radiation oncologist, in an average algorithm runtime of 1-minute-49 s.</p>","PeriodicalId":20185,"journal":{"name":"Physics in medicine and biology","volume":" ","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A robust optimisation genetic algorithm for HDR prostate brachytherapy including all major uncertainties.\",\"authors\":\"Andrew C Kennedy, Michael J J Douglass, Raghavendra V Gowda, Alexandre M C Santos\",\"doi\":\"10.1088/1361-6560/addf0b\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><i>Objective.</i>In high-dose-rate prostate brachytherapy, uncertainties are likely to cause a deviation from the nominal treatment plan, potentially leading to failure in achieving clinical objectives. Robust optimisation has the potential to maximise the probability that objectives are met during treatment despite these uncertainties.<i>Approach.</i>A probabilistic robust optimiser that incorporating fourteen major uncertainty sources was developed and evaluated on 49 patients. Three objective functions were maximised to generate the approximate Pareto front of 200 robust-optimised plans, approximating the robustness of: (1) The minimum dose to the hottest 90% of the prostate (D90P), (2) The maximum dose to the urethra (D0.01 ccU), and (3) The maximum dose to the rectum (D0.1 ccR). Plans were then robustly evaluated using 1000 uncertainty scenarios each simulating a possible deviation from the planned treatment. The percentage of scenarios meeting theD90P,D0.01 ccU, andD0.1 ccRmetrics were determined, along with the overall pass rate, defined as the percentage of scenarios meting all three metrics simultaneously. These pass-rates, along with nominal metrics, were, were used to select the best robust-optimised plan. A radiation oncologist evaluated the best robust-optimised plans against the treatment planning system (TPS)-optimised plan for ten patients. The same selection criteria were then applied to a further cohort of 39 patients and the same plan comparisons performed.<i>Main results</i>. All best robust-optimised plans had higher overall pass-rates (mean: 50.7 ± 1.5%, SD: 14.2%) then TPS-optimised plans (mean: 32.0 ± 1.5%, SD: 12.3%). The meanD0.01 ccUpass-rate was 66.0 ± 1.3% (SD: 12.1) for the robust-optimised plans compared with 47.2 ± 1.3% (SD: 9.3%) for TPS-optimised plans. TheD90Ppass-rates was higher for robust-optimised plans (mean: 85.6 ± 1.1%, SD: 9.5%) then TPS-optimised (mean: 82.2 ± 1.1%, SD: 13.8%) in 36 patients.D0.1 ccRpass-rates remained consistently high for both optimisation methods.<i>Significance</i>. The robust optimisation algorithm generated plans with greater robustness than the TPS-optimised plans for nine out of ten patients evaluated by a radiation oncologist, in an average algorithm runtime of 1-minute-49 s.</p>\",\"PeriodicalId\":20185,\"journal\":{\"name\":\"Physics in medicine and biology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2025-06-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Physics in medicine and biology\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://doi.org/10.1088/1361-6560/addf0b\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENGINEERING, BIOMEDICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Physics in medicine and biology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1088/1361-6560/addf0b","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0

摘要

目的在高剂量率前列腺近距离放射治疗中,不确定性很可能导致与标称治疗计划的偏离,从而可能导致无法达到临床目标。稳健优化的目的是在不确定的情况下实现目标的概率最大化。方法开发了包含14个主要不确定性源的概率稳健优化器,并对49例患者进行了评估。三个目标被最大化,以产生200个鲁棒优化方案的近似帕累托前,逼近鲁棒性:(1)前列腺最热的90%的最小剂量(D90P),(2)尿道的最大剂量(D0.01 ccU),(3)直肠的最大剂量(D0.1 ccR)。然后使用1000种不确定性情景模拟可能的偏差对计划进行稳健评估。确定了满足每个指标的场景的百分比,以及总体通过率,定义为满足所有三个指标的场景的百分比。这些指标与名义指标一起,指导了最佳稳健优化方案的选择。一位放射肿瘤学家比较了十个病人的最佳稳健性优化方案和tps优化方案。然后将相同的选择标准应用于另一个39例患者的队列,并进行相同的计划比较。结果鲁棒优化方案总体通过率(平均:50.7±1.5%,SD: 14.2%)高于tps优化方案(平均:32.0±1.5%,SD: 12.3%)。稳健优化方案的平均D0.01 ccu合格率为66.0±1.3% (SD: 12.1),而tps优化方案的平均D0.01 ccu合格率为47.2±1.3% (SD: 9.3%)。36例患者的d90pass率(平均:85.6±1.1%,SD: 9.5%)高于tps优化方案(平均:82.2±1.1%,SD: 13.8%)。两个计划的通过率都很高。在平均算法运行时间为1分49秒的情况下,鲁棒优化器生成的方案比tps优化方案具有更强的鲁棒性,适用于放射肿瘤学家评估的十分之九的患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A robust optimisation genetic algorithm for HDR prostate brachytherapy including all major uncertainties.

Objective.In high-dose-rate prostate brachytherapy, uncertainties are likely to cause a deviation from the nominal treatment plan, potentially leading to failure in achieving clinical objectives. Robust optimisation has the potential to maximise the probability that objectives are met during treatment despite these uncertainties.Approach.A probabilistic robust optimiser that incorporating fourteen major uncertainty sources was developed and evaluated on 49 patients. Three objective functions were maximised to generate the approximate Pareto front of 200 robust-optimised plans, approximating the robustness of: (1) The minimum dose to the hottest 90% of the prostate (D90P), (2) The maximum dose to the urethra (D0.01 ccU), and (3) The maximum dose to the rectum (D0.1 ccR). Plans were then robustly evaluated using 1000 uncertainty scenarios each simulating a possible deviation from the planned treatment. The percentage of scenarios meeting theD90P,D0.01 ccU, andD0.1 ccRmetrics were determined, along with the overall pass rate, defined as the percentage of scenarios meting all three metrics simultaneously. These pass-rates, along with nominal metrics, were, were used to select the best robust-optimised plan. A radiation oncologist evaluated the best robust-optimised plans against the treatment planning system (TPS)-optimised plan for ten patients. The same selection criteria were then applied to a further cohort of 39 patients and the same plan comparisons performed.Main results. All best robust-optimised plans had higher overall pass-rates (mean: 50.7 ± 1.5%, SD: 14.2%) then TPS-optimised plans (mean: 32.0 ± 1.5%, SD: 12.3%). The meanD0.01 ccUpass-rate was 66.0 ± 1.3% (SD: 12.1) for the robust-optimised plans compared with 47.2 ± 1.3% (SD: 9.3%) for TPS-optimised plans. TheD90Ppass-rates was higher for robust-optimised plans (mean: 85.6 ± 1.1%, SD: 9.5%) then TPS-optimised (mean: 82.2 ± 1.1%, SD: 13.8%) in 36 patients.D0.1 ccRpass-rates remained consistently high for both optimisation methods.Significance. The robust optimisation algorithm generated plans with greater robustness than the TPS-optimised plans for nine out of ten patients evaluated by a radiation oncologist, in an average algorithm runtime of 1-minute-49 s.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Physics in medicine and biology
Physics in medicine and biology 医学-工程:生物医学
CiteScore
6.50
自引率
14.30%
发文量
409
审稿时长
2 months
期刊介绍: The development and application of theoretical, computational and experimental physics to medicine, physiology and biology. Topics covered are: therapy physics (including ionizing and non-ionizing radiation); biomedical imaging (e.g. x-ray, magnetic resonance, ultrasound, optical and nuclear imaging); image-guided interventions; image reconstruction and analysis (including kinetic modelling); artificial intelligence in biomedical physics and analysis; nanoparticles in imaging and therapy; radiobiology; radiation protection and patient dose monitoring; radiation dosimetry
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信